Retromer has emerged as a master conductor of endosomal trafficking, and VPS35 and other retromer-related proteins are found to be deficient in late-onset Alzheimer's disease (AD). Depleting VPS35 in neurons impairs retromer function, affecting for example the trafficking of the amyloid-precursor protein (APP) and the glutamate receptor GluA1. Whether VPS35 repletion, after chronic in vivo depletion, can rescue these impairments remains unknown. Here we set out to address this question by using a viral vector approach for VPS35 repletion. First, we completed a series of studies using neuronal cultures in order to optimize AAV9-VPS35 delivery, and to understand how exogenous VPS35 expression affects its endogenous levels as well as its binding to other retromer proteins. Next, we completed a series of studies in wildtype mice to determine the optimum protocol for in vivo delivery of AAV9-VPS35 to the hippocampus. We relied on this information to deliver AAV9-VPS35 to the hippocampus of mice genetically engineered to have chronic, neuronal-selective, VPS35 depletion.
INTRODUCTION
Retromer is a multi-modular protein assembly that recycles transmembrane proteins out of the endosomal compartment 1 . The 'cargo recognition core' is a central module of retromer function because it is the core to which transported cargo binds, but also because it is with this core that other retromer modules interact VPS35 and other retromer core proteins have been found deficient in the hippocampal formation of patients with late-onset Alzheimer's disease (AD) 3 . When acutely modeled in neurons and cell culture, retromer depletion increases the residence time of the amyloid-precursor protein (APP) in endosomes, accelerating its proteolytic cleavage [4] [5] [6] [7] . Other studies have depleted neuronal VPS35 in hippocampal slices to show that retromer is required for the recycling of the glutamate receptor, ionotropic, AMPA1 alpha 1 (GluA1, also called GluR1) to the cell surface 8 . Since reducing receptor recycling accelerates its degradation, retromer deficiency might account for the GluA1 deficiency observed in AD, a defect that is thought to mediate synaptic pathology [9] [10] [11] [12] in AD.
These and other studies support the conclusion that the chronic VPS35 deficiency observed in AD impairs retromer function and can contribute to the neuronal defects observed in the disease. Lacking, however, is evidence showing that VPS35 repletion, after chronic in vivo depletion, restores retromer function. We therefore generated two new experimental tools: A novel mouse model in which VPS35 is selectively depleted in neurons, and an AAV9 vector that carries the human VPS35 plasmid with which to replete VPS35.
Before beginning in vivo repletion studies, however, we first needed to complete an extensive series of studies in neuronal culture and wildtype mice to optimize the VPS35 transduction protocol, and to understand its consequences in non-depleted neurons. We then completed in vivo VPS35 repletion studies, and find that it restores retromer function, normalizing APP cleavage and glutamate receptor levels in the mouse hippocampus. These studies also unexpectedly showed that VPS35 depletion in neurons secondarily activated glia, similar to the pattern observed in AD, and that repletion of VPS35 in neurons partially abrogated this glial response.
RESULTS

AAV9-VPS35 expression and the endogenous retromer
To determine expression efficacy and optimum delivery, we first C-terminally tagged human VPS35 with green fluorescent protein (GFP), and delivered AAV9-VPS35-GFP to mouse neuronal cultures. Immunoblot levels of endogenous and exogenous VPS35
were measured across three doses. A pattern consistent with autoregulation was observed ( Fig. 1A) , whereby the higher the levels of exogenous VPS35 expressed, the lower the levels of endogenous VPS35 were detected. A significant increase in total VPS35 was observed at both the middle dose (t=10.74, p=0.0004) and highest dose (t=26.02, p=0.00001).
Because VPS35 is a protein that acts as a platform to which other retromer proteins bind, we next tagged the human VPS35 with HA, since it is smaller than GFP and less likely to interfere with VPS35's function. This size difference has also been reported to influence expression levels [13] [14] [15] [16] [17] . We find that AAV9-VPS35-HA, delivered at similar doses, caused higher total VPS35 expression than AAV9-VPS35-GFP (Fig. 1B) .
A co-immunoprecipitation study was performed, using anti-HA antibody, showing that exogenously expressed VPS35 pulls down endogenous VPS29 and VPS26 (Fig. 1C) , thus establishing that exogenous HA-tagged VPS35 binds endogenous retromer core proteins.
AAV9-VPS35 delivered to the mouse hippocampus
Next, to determine the optimum in vivo AAV9-VPS35 delivery we completed 8
experiments (3-6 animals per experiment), delivering AAV9-VPS35-HA intracranially to the dorsal CA1 region of the hippocampus of wildtype mice in varying doses and volumes. Brain slices were generated for fluorescent immunohistochemistry (IHC) and probed with anti-HA antibody to map the degree and distribution of expression, using neuronal and nuclear markers to detect potential toxicity. In parallel, tissue samples from the CA1 were microdissected and processed for immunoblotting to quantify expression levels ( Fig. 2A -Right) .
Using the optimum delivery protocol ( Fig. 2A , left panel), we injected AAV9-VPS35-HA to 3-month old mice that were then aged to 6 months. Results showed a broad expression distribution across the dorsal hippocampus, with a significant increase in VPS35 (t=8.74, p=0.003) with no evidence of toxicity (Fig. 2B , C&D). As in neuronal culture, a co-immunoprecipitation study with anti-HA antibody showed that exogenous VPS35 downregulates the corresponding endogenous protein, and that exogenous VPS35 binds other retromer core proteins (Fig. 2E ).
VPS35 depletion-repletion and neuronal phenotypes
By crossing mice expressing loxP-flanked VPS35 (VPS35 fl/fl ) with mice expressing Cre recombinase under the Camk2α promoter we generated VPS35 neuronal-selective knockout (VPS35 nsKO) mice (Suppl. Fig.) , in whom VPS35 is depleted in forebrain neurons including the hippocampus (Fig. 3A) . Using the optimized protocol, AAV9-VPS35-HA was delivered to the right CA1 region of the VPS35 nsKO mice, and AAV9-GFP was delivered to the contralateral CA1 as control (Fig. 3D ). In addition, VPS35
fl/fl mice were evaluated as non-injected controls.
All mice were injected at 3 months of age and aged to 6 months. VPS35 depletion accelerated APP cleavage, indicated by an increase in its C-terminal fragments (CTFs) (t=15.89, p=0.00009), and a striking reduction in GluA1 levels (t=9.70, p=0.0006). VPS35 repletion for 3 months with AAV9-VPS35-HA normalized APP misprocessing (t=3.88, p=0.018), and completely restored GluA1 levels as shown by immunoblotting (t=6.45, p=0.003), (Fig. 3B&C) , and confirmed by fluorescent IHC (Fig.   3D ).
VPS35 depletion-repletion and glia responses
Depleting neuronal VPS35 was observed to cause an activation of astrocytes, as detected by an increase in GFAP (t=2.74, p=0.052) (Fig. 4A ). VPS35 repletion normalized this response, shown by immunoblotting (t=3.39, p=0.028) and fluorescent IHC (Fig. 4A,C&D) . Exogenous VPS35-HA expression in WT mice had minimal effect on astrocytes at 3 months post-surgery (Fig. 4B ).
Depleting neuronal VPS35 also caused an activation of microglia, as detected by an increase in IBA1 (t=8.24, p=0.001) and CD11b (t=6.65, p=0.002) levels (Fig. 4A&C ).
Immunoblotting showed that VPS35 repletion had a modest, but not statistically significant, effect on IBA1 and CD11b. Again, exogenous VPS35-HA expression in WT mice had minimal effects on microglia at 3 months post-surgery ( Fig. 4B )
By co-labelling we confirmed previous studies, showing that when AAV9 is injected directly into the brain parenchyma it is not expressed in microglia and minimally expressed in astrocytes [18] [19] [20] [21] [22] (Fig. 5A&B ). The culture was maintained for 3 weeks after transduction (4 weeks total). At day 28 the neurons were lysed using RIPA buffer with protease and phosphatase inhibitors.
DISCUSSION
Co-immunoprecipitation. Co-immunoprecipitation was performed as described previously 38,39 with some modifications. Briefly recombinant Protein G Agarose beads (ThermoFisher cat# 15920010) were washed three times with PBS, centrifuged at 1500 g (2 min) and incubated with 3.5-5 ug of primary antibody (anti-HA, ab9110 & anti-GFP, ab290) overnight with constant rocking at 4ºC. Next day the antibody coated beads were washed with cold PBS (4ºC) and pelleted by spinning at 1500 g for 2 min.
Cells (or tissue) were washed twice with cold PBS and homogenized in IP buffer (50mM Tris, 100mM EDTA, 150mM NaCl, pH 7.3). Protein concentration was determined using Pierce BCA protein Assay kit (ThermoFisher cat # 23225). 300-700 ug of protein was prepared in 1100uL of IP buffer. Of this 1100ul, 100ul was saved as total lysate (input) and 1000ul was incubated with antibody coated agarose beads overnight at 4ºC.
Next day the samples (containing beads) were centrifuged at 1500 g for 1 min at 4ºC; the supernatant was collected and labeled as the unbound fraction. Beads were washed 5 times with cold PBS. After the last wash PBS was completely aspirated and proteins were eluted from the beads and samples prepared for loading onto electrophoresis gels by adding 150uL-1X sample buffer (IP buffer 100ul buffer + 35uL of 4X NuPAGE™ LDS Sample Buffer ThermoFisher cat# NP0007, + 15ul of 10X Reducing Agent ThermoFisher Cat# NP0009). After agitating the samples gently they were incubated at 50ºC on water bath for 30 min, mixing well every 10 min. The samples were incubated at 90ºC for 5 min before loading onto NuPAGE® Bis-Tris 4-12% gels.
VPS35 nsKO mice. VPS35 floxed mice were generated at Center for Mouse Genome IRDye® 800 or 680 antibodies (LI-COR) were used as secondary with dilutions of 1:10k for 800CW, 1:15k for 680RD, and 1:25k for 680LT antibodies. Western blots were scanned using the Odyssey imaging system as described previously
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Stereotactic injection of AAV9 in mouse hippocampus. All animal procedures were approved by Columbia University IACUC. AAV9 viral particles were injected into the CA1 region of the mouse brain as described previously 42 with slight modifications.
Briefly, the surgical procedure was carried out in aseptic environment. Animals were anesthetized using ketamine / xylazine. Fur was clipped and the site cleaned with betadine scrub followed by 70% ethanol. Eyes were lubricated with an application of sterile, bland ophthalmic ointment. Preemptive analgesia was induced by carprofen and marcaine injections. Mouse was placed on infra-red warming pad in the stereotaxic frame connected to an automatic injection pump. Surgeon wore proper protective equipment and sterile gloves. Using sterile scissors, skin was cut and bone exposed. A tiny burrhole was placed in the skull at the experimental coordinates calculated using landmarks (bregma and lambda). The dura mater was pierced using a sterile needle and the syringe needle lowered to the desired z coordinate.
AAV9 VPS35-HA virus was injected through 28g needle attached to a hamilton syringe at a rate of 0.2 ul/min over a period of 5 -10 min (1-3 ul volume). Control AAV9 was injected on the contralateral side. Optimal dose was identified using a dose response ranging from 4E+9 to 1E+11 vector genomes. The needle was retracted 5 minutes after the end of injection. Surgical wound was closed/sutured by a combination of skin glue and sterile stitches. Post-surgery 1 ml of normal saline was injected via intraperitoneal route, to minimize dehydration. Infra-red warming pad was used during post op recovery. Animals were monitored continuously until ambulating and once daily for the first 3 days and then twice a week until day 14 post op. Sutures were removed on day 10-14 post op. Animals were survived for 1-3 months post-surgery.
Perfusion and tissue processing. After the survival period, the animals were perfused with saline, the brains extracted and the site of injection (dorsal CA1) was microdissected out of the brain for biochemical analysis. Animals selected for fluorescent IHC analysis were perfused with normal saline followed by 4% PFA and 30% sucrose. The brains were embedded in optimal cutting temperature (OCT Tissuetek Cat# 62550-12) and frozen at -80ºC. Frozen blocks of brains in OCT were sectioned at a Leica CM3050 S cryostat set at 12 microns thickness. Sections were transferred onto Superfrost™ Plus Microscope Slides (Fisher Cat# 12-550-15) and stored at -80ºC.
Fluorescent Immunohistochemistry (IHC).
Standard staining and microscopy techniques were used, as described previously 34,43-45 with some modifications. All washes were done with PBS (1X-PBS containing 0.01% Sodium Azide). Briefly antigen retrieval was performed using Citric Acid buffer (10mM sodium citrate, 1.9mM citric acid, pH6.0) as describe previously [46] [47] [48] [49] . Buffer in a coplin jar was preheated in a microwave (900W, MCD790SW) before immersing the slides. The slides were then heated for 10 minutes in intervals of 3 + 2 + 3 + 2 min with monitoring/replenishing of the buffer level in between the intervals. Buffer and slides were allowed to cool down at room temperature for 30min. Slides were washed once and incubated in 0.03% H 2 O 2 in water for 30min. After one wash sections were permeabilized using 0.01% digitonin (wt/vol) for 10 min and then blocked in 5% donkey serum in PBS (vol/vol) for 1. (ab178846, Abcam, 1:500). Next day after five washes, the sections were incubated for 2 hours with secondary antibody. Secondary antibodies (ThermoFisher) conjugated with alexa fluor dyes were used at a dilution of 1:250 in 1% donkey serum (in PBS).
After 3 washes Hoechst 33258 nuclear stain (ThermoFisher H3569, 1:1500 for 5 min) was used to counter stain the nuclei. After another five washes coverslips were mounted onto the slides with ProLong Gold Antifade Mountant (ThermoFisher P36934).
An alternate protocol was used for staining of VPS35 (ab10099, Abcam, 1:300) (Fig.   3A) . Briefly, 30 µm free-floating horizontal sections were washed three times with PBS and incubated at 4ºC overnight on a rotator in 1 ml of primary antibody diluted in PBS containing 0.3% Triton X-100 (vol/vol) and 5% normal donkey serum (vol/vol). After three washes with PBS-T (0.1% Triton X-100), the sections were incubated for 1 hour with secondary antibody (Donkey-anti-goat, Alexa555 at 1:400, ThermoFisher).
Following three washes with PBS-T, and one wash with PBS, sections were mounted on slides. All images were captured using Zeiss LSM 700 META confocal microscope equipped with a 5x, 20x & 63× Plan-Apochromat objective and HeNE1, HeNe2 and argon lasers.
Statistics. Statistical analysis was performed using Microsoft Excel and SPSS.
Student's t-test was used for all biochemical experiments assuming equal variance.
Independent two-sample t-test with two-tailed distribution and paired t-test were used depending on the type of experimental data. All data are presented as means, the error bars indicate standard error of the mean. All bar graphs were created in GraphPad Prism 8. VPS35 expression in these animals is shown in Fig. 3B 
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A
, e t a l . , e t a l . Homologous recombination was performed in mouse embryonic stem cells (mES) targeting the VPS35 gene at exons 2 to 6. The recombined gene had LoxP sites before exons 3 and after exon 5. G418 and Gancyclovir selection and nested long range PCR were used to identify targeted clones. Targeted ES cells were aggregated into morula to generate chimeric mice. Next the chimeric mice were bred with ROSA26-Flpe to remove the Frtflanked PGKneo cassette. Neuronal-selective VPS35 knockout mice were generated by crossing mice expressing loxP-flanked VPS35 (exons 3-5) (VPS35fl/fl) with mice expressing Cre recombinase under the Camk2α promoter. Camk2a-CRE mice were obtained from Jackson labs (Stock No: 005359) 
